InflaRx N.V. (IFRX)

NMS – Real vaqt narxi. Valyuta: USD

2.43

-0.07 (-2.80%)

Yopilishda: May 12, 2026, 4:00 PM EDT

2.39

-0.04 (-1.65%)

Bozordan keyin: May 12, 2026, 7:45 PM EDT

09.05.2026

InflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases Transcript

08.05.2026

InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline

InflaRx NASDAQ: IFRX outlined plans to prioritize development of izicopan, an oral inhibitor of the C5a receptor (C5aR), in ANCA-associated vasculitis (AAV) and other renal diseases during a company conference call led by CEO and founder Niels Riedemann. Get InflaRx alerts:Sign UpIzicopan positioned as a next-generation C5aR inhibitor Riedemann described izicopan as an oral agent designed to block the C5a receptor, a pathway he called a “critical driver of inflammatory cascade.

08.05.2026

InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares

Jena, Germany, May 08, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that it has completed its underwritten offering of 75,000,000 ordinary shares of the Company at an offering price of $2.00 per ordinary share. The aggregate gross proceeds from the offering were $150 million, before deducting the underwriting discount and offering expenses.

06.05.2026

InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares

Jena, Germany, May 06, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today the pricing of its underwritten offering of 75,000,000 ordinary shares of the Company at an offering price of $2.00 per ordinary share.

06.05.2026

InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases

Jena, Germany, May 06, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it intends to develop izicopan, an oral C5a receptor (C5aR) inhibitor with potential best-in-class properties, in AAV, a life-threatening kidney disorder. InflaRx is conducting Phase 2 planning for izicopan in AAV and is evaluating the feasibility of multiple development approaches, including the potential for an expedited path to the commercial market, in an effort to best address the evolving regulatory environment surrounding the currently approved comparator, avacopan.

04.05.2026

InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes

JENA, Germany, May 04, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced new pre-clinical data demonstrating low reactive metabolite formation of izicopan in human liver microsomes. Reactive metabolite formation is widely used in drug development as an early mechanistic indicator of potential bioactivation-related safety risk.

28.04.2026

InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

JENA, Germany, April 28, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the “Company”), today announced that it has received a written notice (the “Notice”), dated April 27, 2026, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with Nasdaq's minimum bid price requirement set forth under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”).

Videolar

No Data

There is no data to display

Press-relizlar

08.05.2026

InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares

06.05.2026

InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares

06.05.2026

InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases

04.05.2026

InflaRx N.V. (IFRX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

InflaRx N.V. (IFRX)

InflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases Transcript

InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline

InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares

InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares

InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases

InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes

InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

Videolar

No Data

Press-relizlar

InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares

InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares

InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases

InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes

InflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases Transcript

InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline

InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares

InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares

InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases

InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes

InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

Videolar

No Data

Press-relizlar

InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares

InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares

InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases

InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes

Search stocks

InflaRx N.V. (IFRX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

InflaRx N.V. (IFRX)

InflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases Transcript

InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline

InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares

InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares

InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases

InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes

InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

Videolar

No Data

Press-relizlar

InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares

InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares

InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases

InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes

InflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases Transcript

InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline

InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares

InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares

InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases

InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes

InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

Videolar

No Data

Press-relizlar

InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares

InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares

InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases

InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes